Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median effective dose of ocelidine combined with remimazolam for painless gastroscopy in elderly patients
ChiCTR2500103472Phase 4Recruiting
- Sponsor
- Jiaxing Second Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orcetidine and remimazolam in None, sponsored by Jiaxing Second Hospital. Primary endpoint: Reaction to painless gastroscopy insertion. Started May 2025; status: recruiting.
02
Drugs
orcetidineremimazolam
Beyond the preview
Go deeper on ChiCTR2500103472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103472.